v3.26.1
SEVERANCE
12 Months Ended
Dec. 31, 2025
SEVERANCE  
SEVERANCE

25. SEVERANCE

In December 2025, the Company entered into transition and separation agreements with its former Executive Vice President and Chief Clinic Officer and its former Senior Vice President, Sales. In connection with these agreements, the Company recognized severance-related charges of $0.5 million and $0.2 million, respectively, within salary, payroll tax, and bonus expense for the year ended December 31, 2025. As of December 31, 2025, the unpaid portion of these separation benefits is included in accrued liabilities on the Consolidated Balance Sheet.